| INTRODUCTION
Stroke is now the leading cause of disease and disability in sub-Saharan Africa (SSA). 1 As stroke survivor populations are diverse, and interaction between illness and contextual factors is important in determining the clinical course of diseases, 2 the characteristics of stroke patients can be expected to differ between SSA and more developed parts of the world.
Along with cognitive impairment, both anxiety and depression are the foremost complications prioritized by stroke survivors and carers. 3 Anxiety and depression have been linked to poorer clinical outcomes and quality of life after stroke because they adversely influence compliance with recommended post-stroke therapies. 4 Yet, studies on emotional disturbances after stroke have mostly focused on depression.
Rates of anxiety reported in stroke survivors are far higher than those in the general population, 5 and the prevalence and severity of post-stroke anxiety (PSA) are similar to those reported for post-stroke depression (PSD) across the clinical course after stroke. 6 Also, depression and anxiety are highly comorbid conditions in stroke survivors, 
| Measures
Stroke survivors meeting study criteria underwent baseline assessments within the first month of stroke.
Anxiety was ascertained using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). 13 The HADS was developed for the assessment of emotional disturbances in non-psychiatric patients within a hospital setting. It includes a total of 14 items each with a score of between 0 and 3. One half of the items are related to anxiety while the other half is specific for depression. The developers of the scale recommend a cut-off ≥11 for the ascertainment of "probable" cases in research. This score is also often used in the determination of clinically significant anxiety. Lower scores of between 8-10/11 are recommended for less severe anxiety symptoms. The HADS has been previously validated in Nigeria 14 where the HADS-A was found to have a sensitivity ranging 85.0%-92.9% and a specificity of 86.5%-90.0%.
Cognitive functioning was assessed using the CSID. 15 The instrument includes a global cognitive test and informant account of patient's ability to cope with activities of daily life. The CSID has been validated in Nigeria, 16 where a total score of ≤23.9 validly suggests cognitive impairment. The Yoruba (Nigerian) version of the CSID is widely used to screen for cognitive functioning in the general and older adults population, including stroke survivors. 
| Other data collection
The following information was obtained from all participants using a standardized questionnaire: demographic data, personal history of smoking, alcohol consumption, and physical activities, medical history of hypertension, diabetes, hyperlipidaemia and heart disease, the use of medications for these conditions, and family history. Information on dietary patterns was obtained using the food frequency questionnaire. The severity of stroke was ascertained using the National 
| Statistical analyses
Stroke survivors with clinically significant anxiety were those who had a score of 11 or more on the HADS-A instrument. Survivors meeting criteria for clinically significant anxiety, but also had a score of ≥11 in the depression subscale of the HADS, were categorized as having anxiety and depression comorbidity. Frequencies and proportions were used to summarize discrete variables. We also examined the prevalence of milder forms anxiety (ie which may not be the focus of clinical attention). For this analysis, we determined the frequency of stroke survivors who scored between 8 and 11 in the HADS-A. 13 We next examined the association of anxiety with demographic and other stroke risk factor variables. These associations were conducted by first comparing stroke survivors with anxiety with those who were anxiety free using the chi 2 test for categorical variables.
We estimated odds ratios of the associations using logistic regression analyses. The same method was used in the investigation of the association of anxiety with cognitive impairment. We note that this particular analysis was exploratory and did not set out to build a definitive model for predicting post-stroke cognitive impairment. As such the ratio of the number of events per variable was smaller than often recommended. 19 We adjusted for the effect of age, gender and education in all regression models. The results of the associations are presented as odds ratios with 95% confidence intervals (CI). Analyses were conducted using Stata MP version 14.0 (StataCorp, College Station, TX, USA). 19 Values of P<.05 were considered significant.
| RESULTS

| Subject characteristics
There were 249 males and 142 females in the study sample (Table 1) .
Their mean age was 57.3 (±11.7) years. There was no significant difference in the mean age for men (57.4±12.2) and women (57.0±10.8).
Over 90% of the subject had at least 6 years of formal education.
Nearly all participants in this study had either mild or moderate stroke (Table 1) .
| Anxiety
A total of 77 (19.7%) stroke survivors had clinically significant PSA.
About 71.4% of participants with PSA also had comorbid depression.
Milder forms of anxiety were present in over one half of participants T A B L E 1 Characteristics of stroke survivors in the study in our sample (Table 2) . Female participants were significantly more likely to be anxious in both unadjusted and adjusted analyses (Table 3 ).
| Anxiety and cognitive impairment
Twenty four (6.1%) participants in the study were cognitively impaired. Those who had cognitive impairment were mostly depressed (81.1%) male (75%) participants. Having cognitive impairment was significantly associated with PSA (Table 4) .
| DISCUSSION
We found a prevalence of 19.7% for PSA and 14.1% for anxiety and depression comorbidity among recent stroke survivors in this SSA setting. Being female independently predicted PSA. Anxiety in stroke survivors was associated with cognitive impairment.
There are no studies of anxiety in survivors of a recent stroke, diagnosed using standard neuroimaging criteria, 11 in SSA to which our results could be meaningfully compared. However, we identified one previous community-based study of 51 self-reported stroke survivors 20 in rural Tanzania who were assessed for anxiety between 6 months and 6 years post-stroke. That study 20 reported an unusually low prevalence of 5.9% for clinically significant PSA. Our results are more reflective of the pattern reported in studies from other parts of the world where methodologies similar to those of the present investigation have been used. In the most recent systematic review of all such studies (N=11), Campbell Burton and colleagues 6 reported an overall prevalence of 18% for PSA. Anxiety prevalence rates of 21%
were reported in assessments conducted at less than 1 month, 21 and 24% when anxiety was ascertained at 1 month post-stroke. 22 In this study, PSA was ascertained in survivors within 1 month of the stroke.
Given rates such as 4.1% 23 and 5.6% 24 reported for any anxiety in the general Nigerian population, the suggestion from our study is that having a recent stroke in the country context leads to a fourfold increase in clinically significant anxiety. As in physical disorders, some variations in the rates of mental health disorders can be expected in studies conducted in different countries and across cultures. For example, assessment instruments may perform differently as cultural nuances may affect the likelihood that respondent will endorse some of the symptoms required to make diagnoses of anxiety disorders. We have other reasons to suspect that the prevalence of criteriondiagnosed PSA found in the present study is likely to be an underestimation of the true picture in this SSA n setting. First, in ascertaining clinically significant anxiety, which is anxiety of sufficient severity to warrant specific interventions, we have focused on the more stringent diagnostic cut-off scores for the HADS, and as recommended by the developers of the instruments. Some reports from the general Nigeria population 29 suggest that many persons with milder severity of anxiety have levels of anxiety-related disability that overlap with those of anxiety syndromes diagnosed using stricter criteria. Second, a suggestion of mental illness is still associated with perceived stigma in the Nigerian context. 30 As such, it is possible that some of the respondents in the present study may have been too embarrassed to admit to some of the anxiety-related symptoms. Others may especially find it unusual to reveal health information to non-clinician assessors. Third, stroke survivors in the present study were identified as part of a randomized controlled trial (RCT). Persons who were too ill to provide subsequent follow-up information were excluded, thus,
Analyses showing participants with milder forms of anxiety in the sample | 621 suggesting that the sample for the present study may not be typical of the full spectrum of stroke survivor population in the study setting.
For example, nearly all participants in the present study had stroke of mild or moderate severity. It is reasonable to expect that persons with more severe stroke may likely to have more physical and mental health morbidity.
Most of the risk factors we investigated were not associated with anxiety in our stroke survivors. The association between female gender and anxiety found in this study has been inconsistently reported in both stroke 6 and general Nigerian population studies. 23 However, over 70% of persons with PSA in our sample also had comorbid depression of equivalent severity. As it is well established in both general 31 and stroke populations globally 32 that depression is commoner in women, we suspect that gender differential in the prevalence of PSA in our study is the result of very high overlap between anxiety and depression in the studied sample.
Similar to gender, the finding in the present study of an association between PSA and cognitive impairment is inconsistently reported in the literature. 7, 33 However, along with the high overlap between depression and PSA in our sample, over 80% of those with cognitive impairment were also depressed. We were, thus, not surprised about the association of PSA (which is over 70% PSD in our sample) with cognitive impairment found in the present study.
This study has a few limitations. First, because of its cross-sectional nature of the analyses, we were unable to differentiate whether the anxiety in our sample of recent stroke survivors predated the stroke event or were incident cases. We note the possible bidirectional relationship between emotional disorders such as anxiety and stroke, with each serving as important risk factor for the other. 34 Cross-sectional analyses are inadequate in providing robust evidence for the direction of associations between health conditions. Second, even though the HADS is widely used with good validity in stroke populations across cultures, it is unable to make substantive diagnoses of anxiety disorders. Finally and as previously stated, the present sample was drawn from a RCT and is unlikely to represent the entire spectrum of stroke survivors.
In conclusion, we have found in this relatively large sample of recent stroke survivors from SSA that about one in five had clinically significant anxiety, and well over 70% of those with anxiety also have depression. We suspect that these estimates are conservative because of cultural and study-design peculiarities. Future studies in SSA will need to determine, prospectively, the specific impact of anxiety on clinical processes and stroke outcomes in the population.
T A B L E 4 Independent association of post-stroke anxiety and cognitive impairment in the sample of recent stroke survivors
Variables
Anxiety vs no anxiety
OR (95% CI)
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